Regenetech Completes $2.5 Million Equity Financing
Regenetech, Inc., the tissue regeneration adult stem cell company which has built upon NASA licensed technology, today announced that it has raised approximately $2.5 million via a significant round of equity financing. The financing was completed with Royal Securities Co., a brokerage firm acting in conjunction with Outrider Investors.
David Bonner, CEO of Regenetech, commented, “This financing will help facilitate near-term revenue generation opportunities, including the launch of market focused subsidiaries, such as orthopedics. In addition, it will facilitate continued development of our strong cellXpansion™ technology, which we believe will enable widespread use of adult stem cells for multiple therapies.”
The Company has a dual track revenue strategy to maintain a balance between short and medium term earnings. Near term, Regenetech is targeting two major areas of regenerative therapy that will generate significant early cash flow: veterinary orthopedic applications of its Time-Varying Electromagnetic Field (TVEMF) technology for bone healing, and adult stem cell expansion to support clinical trials, stem cell therapy, and stem cell banking.
Royal Securities Co. is a West Michigan investment brokerage firm that provides full range of brokerage services to both retail and institutional investors.
Outrider Investors, LLC coordinates a network of individuals investing in companies with significant global market opportunity.
Regenetech is a Houston Technology Center Client Company. Houston Technology Center (HTC) is a business accelerator that assists Houston-based emerging technology companies in key sectors such as: Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies. See www.houstontech.org for more information.
Forward Looking Statements: The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The statements contained in this document that are not historical facts (including without limitation statements to the effect that Regenetech, Inc. (the "Company" or "Regenetech") or its management "believes," "expects," "anticipates," "plans," or other similar expressions) are forward-looking statements based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those anticipated by the Company. These forward-looking statements involve significant risks and uncertainties (some of which are beyond the control of the Company) and assumptions and are subject to change based upon various factors. Should these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may vary in material respects from those projected in the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.